NEW YORK (Dow Jones)--Dendreon Corp. (DNDN) said sales of its controversial
prostate cancer drug Provenge are growing slower than expected because
doctors aren't comfortable with the complex task of getting reimbursed for
the expensive treatment. As a result, the Seattle drug maker withdrew its
sales expectations for the year and announced plans to cut jobs. Shares of
Dendreon fell 62% to $13.66 in after-hours trading Thursday.
